VC and Investment
Pharmaceutical
India’s pharmaceutical sector is undergoing a structural shift, with diabetes therapies and cardiac care driving growth well above the broader market. 3 August 2026
Today's issue
Refine search
Biotechnology
US biotech Jasper Therapeutics has completed its all-stock acquisition of complement-focused Kira Pharmaceuticals, creating a combined immunology company with a broader biologics pipeline for immune-mediated diseases. 17 July 2026
Biotechnology
Australian radiopharmaceutical company AdvanCell has closed an oversubscribed and upsized $315 million Series D financing to advance its targeted alpha therapy pipeline and expand its manufacturing network. 15 July 2026
Pharmaceutical
US AI drug discovery firm Chai Discovery has raised $400 million in a Series C financing, valuing the San Francisco-based company at $3.8 billion as it looks to expand use of its molecular design platform across the pharma industry. 15 July 2026
Biotechnology
Cambridge, USA-based biotech Spero Therapeutics on Tuesday announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR. 15 July 2026
Biotechnology
US commercial-stage biotech Mighty Therapeutics today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. 14 July 2026
Pharmaceutical
Clinical-stage biopharmaceutical company Draig Therapeutics has closed an oversubscribed $65 million Series B financing to support development of its neuropsychiatry pipeline, led by the Phase II major depressive disorder candidate DT-101. 14 July 2026
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Biotechnology
US immune-oncology drug developer Agenus’ stock surged more than 125% to $7.57 in morning trading on Monday, after it announced a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. 14 July 2026
Biotechnology
The biotech infrastructure sector has changed significantly since the biotechnology funding peak of 2021. 14 July 2026
Biotechnology
Barcelona, Spain-based CriteriaCaixa, the holding company that manages the business assets of ‘la Caixa’ Banking Foundation, today announces a reboot of its start-up investment business to facilitate the growth of science and technology-based high-potential emerging companies. 13 July 2026
Pharmaceutical
Sweden-based KDventures AB today announced that its portfolio company PharmNovo has completed a capital raise of approximately 39 million kronor ($4.1 million), with participation from external investors. 10 July 2026
Biotechnology
China’s MindRank AI has completed a $52 million Series B financing round, with investors including leading renminbi and US dollar funds. Kaiwu Capital served as the exclusive financial advisor. 9 July 2026
Biotechnology
UK biotech company Alchemab Therapeutics has secured a £25 million ($34 million) Series A extension from the British Business Bank, in what the Bank says is its largest direct investment in a life sciences company. 9 July 2026
Biotechnology
French genetic medicines company Cyllene Therapeutics has raised 33 million euros ($38 million) in series C financing to support development of its lead neuro-urology candidate EG110A, as the company rebrands from EG 427 and moves closer to late-stage clinical testing. 8 July 2026
Biotechnology
Biopharma coverage often focuses on two parts of the industry: the largest global drugmakers and the smallest venture-backed biotech companies. Between them sits a broad group of mid-sized regional companies that play an important role in how medicines are developed, manufactured, licensed and commercialized. 7 July 2026
Biotechnology
French inflammatory diseases specialist Abivax yesterday announced the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares (ADSs). 7 July 2026
Biotechnology
Scribe Therapeutics, a Phase I biotech developing CRISPR therapies for cardiovascular diseases, filed on Thursday with the Securities & Exchange Commission (SEC) to raise up to $75 million in an initial public offering. 3 July 2026
Biotechnology
New York, USA-based clinical-stage biotech Neurogene, which is focused on developing genetic medicines for rare neurological diseases, announced the pricing of its public offering of 3,500,000 shares of common stock at $30.00 per share. 3 July 2026
Biotechnology
UK biotherapeutics company PureTech Health says its founded entity Celea Therapeutics has completed a $180 million financing to advance deupirfenidone (LYT-100), an investigational treatment for idiopathic pulmonary fibrosis (IPF), into Phase III testing. 2 July 2026
Pharmaceutical
France’s Abivax today announced the pricing of its previously announced underwritten public offering of 6,400,000 American Depositary Shares (ADSs) each representing one ordinary share, 0.01 euro nominal value per share of the company, in the USA at an offering price of $125.00 per ADS, raising approximately $800 million (702 million euros). 1 July 2026
Biotechnology
Vedanta Biosciences, a Cambridge, Massachusetts-based late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal disease, has secured $60 million in funding and named two new board appointments ahead of pivotal Phase III data for its lead candidate. 7 August 2026
Biotechnology
Mironid, a Glasgow-based biopharmaceutical company developing small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), has raised $46 million in a Series B financing round. 5 August 2026
Biotechnology
US clinical-stage biotechnology company Expedition Therapeutics, which is developing novel oral small molecule therapies for inflammatory and respiratory diseases, today announced the closing of an oversubscribed $115 million Series B financing. 5 August 2026
Pharmaceutical
India’s pharmaceutical sector is undergoing a structural shift, with diabetes therapies and cardiac care driving growth well above the broader market. 3 August 2026
Pharmaceutical
US radiopharmaceutical developer Ratio Therapeutics has closed a $70 million Series C financing to move its targeted radiotherapy pipeline through clinical development and expand the manufacturing capacity needed to supply its programs. 3 August 2026
Biotechnology
California-based Attovia Therapeutics has set terms for a Nasdaq listing, planning to sell 12.5 million shares at $15 to $17 each in its initial public offering. At the midpoint that would net about $182.4 million and, added to the $132.6 million it held at the end of March, fund the immunology specialist into 2029. It has applied to trade under the ticker ATTO. 31 July 2026
Biotechnology
US biotech Braveheart Bio has set terms for an initial public offering that could rank among the year's larger biotech listings, aiming to sell about 18.7 million shares at $15 to $17 apiece and net roughly $274.5 million at the midpoint. It has applied to list on the Nasdaq under the ticker BRVE. 31 July 2026
Pharmaceutical
North Carolina biotech Vogenx is aiming for the smallest of a recent cluster of biotech listings, proposing to sell 6.25 million shares at $11 to $13 apiece in its initial public offering. At the midpoint the deal would net about $67.8 million. The metabolic disease specialist has applied to list on the Nasdaq under the ticker VOGX. 31 July 2026
Biotechnology
Ractigen Therapeutics, a Chinese biotech company working on small activating RNA (saRNA) medicines, has closed a financing round of more than 200 million yuan ($31 million). Guozhong Capital led the raise, with participation from a clutch of domestic investors and returning backer Longmen Capital, which took part for a third straight round. 30 July 2026
Biotechnology
US biotech Inovio has priced a $20 million public share offering, handing it fresh cash to lean on as it approaches a make-or-break regulatory decision this autumn on its lead candidate for a rare and debilitating airway disease. 30 July 2026
Biotechnology
US late-stage biotech Claris Biotherapies today announced multiple key milestones, including the close of a $118 million Series B financing and key executive and board appointments. 28 July 2026
Biotechnology
US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep apnea (OSA) therapy, Oxnimbi (AD109). 28 July 2026
Pharmaceutical
Germany’s Fresenius is further expanding its access to innovation networks through its own corporate venture capital fund. 23 July 2026
Pharmaceutical
A young California start-up wants to do for drug development what enterprise software did for accounting and sales: put the whole thing in one connected system. Cheiron, based in Los Altos, has raised $8 million in seed funding to build what it calls an AI-native operating system for drug programs. 23 July 2026
Pharmaceutical
USA-based gout specialist Crystalys Therapeutics has closed an oversubscribed $130 million series B financing to fund late-stage global development and commercial preparation for its lead drug dotinurad, an oral URAT1 inhibitor. The San Diego biotech, which is still built around this single asset, raised the money less than a year after a $205 million series A. 23 July 2026
Biotechnology
US biotech Regenxbio on Friday announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions. 20 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Biotechnology
USA-based biotech Latigo Biotherapeutics has thrown open its books to public investors, using a Friday filing with the Securities and Exchange Commission to reveal mid-stage results for its lead non-opioid pain candidate LTG-001 while laying out plans to raise fresh capital through a stock market debut. 20 July 2026
Biotechnology
UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion ($2.84 billion), including a record £2.05 billion in venture capital, according to new figures from the BioIndustry Association (BIA). 20 July 2026
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock
market debuts in biopharma history. With IPOs regularly topping the $200m mark,
the amount of money raised in the first half of the year has eclipsed what the entire
sector managed in the whole of 2025. 17 July 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze